CBI court discharges former joint drugs controller in 2022 Biocon bribery base

A discharge means the court found insufficient grounds to proceed with a criminal trial. It is different from a conviction or acquittal after a full trial. Here, the special CBI court at Rouse Avenue examined the allegations against Dr. S. Eswara Reddy and three others in the 2022 Biocon bribery case.

The court said the CBI failed to establish a prima facie case. It found no direct or circumstantial evidence that Reddy demanded a bribe, and no sufficient material proving criminal conspiracy. The order also rejected claims that he improperly expedited Biocon’s regulatory proposal.

The four accused were discharged under Section 250 of the Bharatiya Nagarik Suraksha Sanhita, 2023, corresponding to Section 227 of the Criminal Procedure Code. This means the case will not proceed to trial against them on the evidence examined at this stage. Reddy said the order brought substantial relief.

Prima facie means “at first view.” In criminal procedure, a prima facie case exists when the prosecution presents enough initial material for a court to believe that an offence may have occurred and that the accused may be connected to it. It is a threshold for continuing proceedings, not a final finding of guilt.

The court said the CBI’s allegations did not raise even mere suspicion, let alone grave suspicion. It found no direct or circumstantial evidence of a bribe demand by Reddy. The agency also failed to explain when, where and how he allegedly sought ₹9 lakh.

Because the prosecution did not cross this initial threshold, the court ruled that no prima facie charge was made out. The accused were therefore discharged instead of being sent to trial. The decision focused on the evidence presented at the discharge stage, not on a trial verdict after witness examination.

Dr. S. Eswara Reddy was alleged to have demanded a ₹9 lakh bribe. The allegation mattered because a demand for an undue advantage is a central element in a bribery case under Section 7 of the Prevention of Corruption Act. The court examined whether the prosecution had supplied evidence supporting that specific claim.

It found no direct or circumstantial evidence of the alleged demand. In particular, the prosecution did not establish “when, where and how” Reddy supposedly sought the money. The court also stressed that accepting a bribe must be proved along with the demand to establish the alleged offence.

As a result, the ₹9 lakh allegation remained unsupported at the required preliminary stage. The court concluded that the evidence did not create even mere suspicion, let alone grave suspicion. This failure contributed to Reddy’s discharge and prevented the case from moving forward to trial.

Demand and acceptance serve different purposes in a bribery allegation. Demand shows that the public servant sought an undue advantage. Acceptance shows that the alleged advantage was received. Together, they connect the official’s conduct to the prohibited exchange required for the offence described under Section 7.

The court applied this principle to Reddy’s case. It said both demanding and accepting a bribe were absolute prerequisites. The prosecution provided no direct or circumstantial evidence of a demand and could not show when, where or how Reddy allegedly sought ₹9 lakh. The court therefore found the essential foundation missing.

This requirement protects against treating an unexplained payment or suspicion as proof of bribery. It also gives the accused a clear allegation to answer. In this case, the absence of evidence about the demand meant the CBI could not establish a prima facie Section 7 case, so Reddy was discharged.

The Central Drugs Standard Control Organisation, or CDSCO, is India’s national regulator for medicines and related health products. It sets standards and oversees regulatory decisions, including clinical-trial permissions, drug approvals and monitoring of product quality and safety. It works through technical officers and expert bodies within the national system.

The Drugs Controller General of India, or DCGI, is the senior regulatory official associated with CDSCO. The DCGI leads or oversees important national decisions on medicines, clinical trials and biological products. In the case, Reddy was a former joint drugs controller at CDSCO and had been shortlisted for the DCGI post in 2022.

Their responsibilities matter because medicines must meet standards before approval and continued use. The article’s case involved Biocon Biologics’ Insulin Aspart injection and an alleged waiver of Phase III trials. The court found the proposal reached the expert committee through standard official emails, without Reddy’s intervention.

Phase III clinical trials are large studies conducted after earlier testing suggests that a medicine may work and appear reasonably safe. They compare outcomes in many patients and provide important evidence about effectiveness, side effects and the balance between benefits and risks. Regulators use this evidence when deciding whether a product should be approved.

For Biocon Biologics’ Insulin Aspart injection, waiving Phase III trials could have allowed the approval process to move forward without that standard large-scale evidence stage. The article says the proposal reached the subject expert committee through standard official emails. It also says the court found no evidence that Reddy intervened improperly to expedite the waiver.

A waiver can reduce time and cost, but it may also require strong justification and other evidence. The article does not state why the waiver was proposed or whether it was granted. It records only that the court rejected the claim of improper intervention and found no prima facie criminal case.

Expert committees and regulatory agencies create checks before new medicines reach patients. Scientists and clinicians review evidence about quality, safety and effectiveness. Regulators then decide whether the evidence supports approval, whether conditions are needed and how the product should be monitored. This process aims to control risks without blocking useful treatments unnecessarily.

In the case, Biocon Biologics’ proposal concerning a waiver of Phase III trials for Insulin Aspart injection reached the subject expert committee through standard official emails. The court found no evidence that Reddy intervened in that route. This example shows how formal review channels can separate scientific assessment from an individual official’s alleged influence.

These safeguards matter because approval decisions affect many patients. They also provide records that can be examined if misconduct is alleged. The court found insufficient material to prove that Reddy dishonestly performed official duties for an undue advantage. The article gives no further decision about the product’s approval or future monitoring.